BioArctic AB (publ)
SSE:BIOA-B.ST
227.8 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BioArctic AB (publ) |
Symbool | BIOA-B.ST |
Munteenheid | SEK |
Prijs | 227.8 |
Beurswaarde | 16,779,748,000 |
Dividendpercentage | 0% |
52-weken bereik | 191.5 - 392 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gunilla Osswald Ph.D. |
Website | https://www.bioarctic.se |
An error occurred while fetching data.
Over BioArctic AB (publ)
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)